OmniAb, Inc. (OABI) Stock Analysis & Investment Frameworks
OmniAb, Inc. (OABI) stock analysis on Invetso. Review OmniAb, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
OmniAb, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
OmniAb, Inc. Key Financial Metrics
- Market Cap: $740.76M
- Revenue: $18.67M
- ROE: -16.59%
- ROIC: -17.24%
- Dividend Yield: N/A
About OmniAb, Inc.
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
OmniAb, Inc. Investment Frameworks
Invetso analyzes OmniAb, Inc. (OABI) across the following frameworks:
- OmniAb, Inc. 10Y Growth Potential
- OmniAb, Inc. Scenario Analysis
- OmniAb, Inc. Risks & Opportunities
- OmniAb, Inc. Economic Moat
- OmniAb, Inc. Business Model
- OmniAb, Inc. Management
- OmniAb, Inc. SWOT Analysis
- OmniAb, Inc. Porter's 5 Forces
- OmniAb, Inc. PESTLE Analysis
- OmniAb, Inc. ESG Analysis